RaymondEdwardJosephMD

PubMed

• 17 citations
  Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease.
  Antonio Tursi, R Joseph, Paul Streck> ;Digestive Diseases and Sciences. 2011 May 13
• 3 citations
  MMX Mesalamine for Induction and Maintenance Therapy in Mild-to-Moderate Ulcerative Colitis.
  Stephen B Hanauer, Gary R Lichtenstein, Michael A Kamm, William J Sandborn, Kirstin H Lees, Karen Barrett, Robyn G Karlstadt, Ron Diebold, Raymond E Joseph> ;Gastroenterology & Hepatology. 2009 Jul 1
• 73 citations
  Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis.
  Michael A. Kamm, Gary R. Lichtenstein, William J. Sandborn, Stefan Schreiber, Kirstin Lees, Karen Barrett, R Joseph> ;Inflammatory Bowel Diseases. 2009 Jan 1
• 263 citations
  Once-Daily, High-Concentration MMX Mesalamine in Active Ulcerative Colitis
  Michael A. Kamm, William J. Sandborn, Miguel A. Gassull, Stefan Schreiber, Lechoslaw Jackowski, Todd Butler, Andrew Lyne, David Stephenson, Mary Palmen, R Joseph> ;Gastroenterology. 2007 Jan 1
• 217 citations
  Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
  Gary R. Lichtenstein, Michael A. Kamm, Prabhakar Boddu, Natalya Gubergrits, Andrew Lyne, Todd Butler, Kirstin Lees, R Joseph, William J. Sandborn> ;Clinical Gastroenterology and Hepatology. 2007 Jan 1
• 3 citations
  Solitary colonic ulcer in a spinal cord injured patient.
  Larry Bernstein, Raymond Joseph, William E. Staas> ;Archives of Physical Medicine and Rehabilitation. 1986 Mar 1
• 48 citations
  Structure of Bile Acids Associated with Secretion in the Rat Cecum
  Susan Gordon, M. Dean Kinsey, J.S. Magen, Raymond Joseph, O.D. Kowlessar> ;Gastroenterology. 1978 May 1
• Join now to see all

Journal Articles

• A Dual-Action, Low-Volume Bowel Cleanser Administered the Day Before Colonoscopy: Results from the SEE CLEAR II Study  
  Katz P, Rex D, Epstein M, Grandhi N, Vanner S, Hookey L, Alderfer V, Joseph R, American Journal of Gastroenterology, 1/1/2013
• Expanded Applications: The Potential usage of Mesalamine in Diverticular Disease  
  Tursi, A., Joseph, R.E., Streck, P., Dig Dis Sci, 1/1/2011
• MMX Mesalamine for Induction and Maintenance Therapy in Mild-to-Moderate Ulcerative Colitis  
  Hanauer SB, Lichtenstein GR, Kamm MA, Sandborn WJ, Lees KH, Barrett K, Karlstadt RG, Diebold R, and Joseph R, Gastroenterol Hepatol (N Y), 1/1/2009
• Randomised trial of once- or twice-daily MMX�mesalazine for maintenance of remission in ulcerative colitis  
  Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees KH, Barrett K, Joseph RE, Gut, 1/13/2008
• Once- or twice-daily MMX�mesalazine (24G/day) is effective for the maintenance of remission to mild-to-moderate ulcerative colitis regardless of the mesalazine dose or...  
  Colombel JF, Diebold R, Karlstadt R, Barrett K, Joseph RE, J Crohns Colitis, 1/1/2008
• Prolonged therapy with MMX�mesalazine in patients with acute, mild-to-moderate ulcerative colitis who fail initial mesalazine treatment may avoid the need for therapeu...  
  Kamm MA, Panaccione R, Barrett K, Lees K, Joseph RE, J Crohns Colitis, 1/1/2008
• MMX�mesalazine as the sole medication for the induction of remission and prevention of relapse in mild-to-moderate ulcerative colitis (UC)  
  Panaccione R, Diebold R, Barrett K, Karlstadt R, Joseph RE, Canadian Journal of Gastroenterology, 1/1/2008
• Patients (PTS) with quiescent mild-to-moderate ulcerative colitis (UC) receiving a multiple-daily dose mesalamine formulation can change to once- or twice-daily MMX�me...  
  Sandborn WJ, Karlstadt R, Barrett K, Joseph RE, Canadian Journal of Gastroenterology, 1/1/2008
• Prolonged therapy with MMX�mesalazine for the induction of remission of active, mild-to-moderate ulcerative colitis (UC)  
  Sandborn W, Barrett K, Lees K, Joseph RE, Canadian Journal of Gastroenterology, 1/1/2008
• Maintenance of remission in patients with ulcerative colitis with once- or twice-daily MMX�mesalazine: results of an international multicenter randomized trial  
  Schreiber S, Barrett K, Lees K, Joseph RE, J Crohns Colitis, 1/1/2008
• MMX Multi Matrix System�mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized double-bl...  
  Sandborn WJ, Kamm MA, Lichtenstein GR, Lyne A, Butler T, Joseph RE, Alimentary Pharmacology and Therapeutics, 1/30/2007
• Time to initial symptom resolution with MMX � mesalamine therapy for active, mild-to-moderate ulcerative colitis  
  Sandborn WJ, Karlstadt R, Barrett K, Joseph RE, American Journal of Gastroenterology, 1/1/2007
• MMX � mesalamine is effective for the maintenance of ulcerative colitis remission in both left-sided and extensive disease  
  Lichtenstein GR, Kamm MA, Karlstadt R, Diebold R, Barrett K, Joseph RE, American Journal of Gastroenterology, 1/1/2007
• MMX�mesalazine is Effective for the Maintenance of Remission of Mild-to-Moderate Ulcerative colitis Irrespective of Patients Previous Relapse History  
  Sandborn WJ, Karlstadt R, Barrett K, Joseph RE, American Journal of Gastroenterology, 1/1/2007
• MMX�mesalazine Is Effective for the Maintenance of Ulcerative Colitis Remission in Both Left-Sided and Extensive Disease  
  Lichtenstein GR, Kamm MA, Karlstadt R, Diebold R, Barrett K, Joseph RE, American Journal of Gastroenterology, 1/1/2007
• Long-Term Remission Rates in Patients with Mild-to-Moderate Ulcerative Colitis Who Require an MMX�Mesalazine Dose Increase To Induce Initial Remission  
  Hanauer SB, Kamm MA, Diebold R, Barrett K, Joseph R, American Journal of Gastroenterology, 1/1/2007
• The Effect of Sigmoidoscopy Score at the Start of 5-Aminosalicylic Acid Therapy on Long Term Remission Rates in Patients with Mild-to-Moderate Ulcerative Colitis  
  Lichtenstein GR, Diebold R, Karlstadt RG, Barrett K, Joseph RE, Gastroenterology, 1/1/2007
• Patients with Quiescent Mild-to-Moderate Ulcerative Colitis Receiving a Multiple-Daily Dose 5-Aminosalicylic Acid Formulation Can Maintain Remission with Once- or Twic...  
  Lichtenstein GR, Diebold R, Karlstadt RG, Barrett K, Joseph RE, Gastroenterology, 1/1/2007
• Once- or Twice-Daily MMX�mesalazine for the Maintenance of Remission of Mild or moderate Ulcerative Colitis  
  Panaccione R, Kamm MA, Karlstadt R, Diebold R, Barrett K, Joseph RE, American Journal of Gastroenterology, 1/1/2007
• MMX�mesalazine for the Treatment of Active Mild-to-Moderate Ulcerative Colitis: An Evidence-Based Medicine Analysis  
  Sandborn WJ, Lichtenstein GR, Kamm MA, Barrett K, Joseph RE, American Journal of Gastroenterology, 1/1/2007
• MMX�mesalazine effectively induces remission of mild-to-moderate ulcerative colitis regardless of age  
  Sandborn WJ, Lichtenstein GR, Kamm MA, Barrett K, Joseph RE, Canadian Journal of Gastroenterology, 1/1/2007
• MMX�mesalazine induces complete mucosal healing in patients with mild-to-moderate ulcerative colitis  
  Sandborn WJ, Lichtenstein GR, Kamm MA, Barrett K, Joseph RE, Canadian Journal of Gastroenterology, 1/1/2007
• The effect of prolonged therapy with MMX � mesalamine in patients with acute, mild-to-moderate ulcerative colitis  
  Lichtenstein GR, Kamm MA, Panaccione R, Barrett K, Lees K, Joseph RE, American Journal of Gastroenterology, 1/1/2007
• Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis; a phase II, dose-ranging study  
  D'Haens G, Hommes D, Engels L, Baert F, Van der Waaij L, Connor P, Ramage J, Dewit O, Palmen M, Stephenson D, Joseph R, Alimentary Pharmacology and Therapeutics, 1/1/2006
• Persistence with pharmacotherapy for gastrointestinal disease: associated costs of health care  
  Shaya FT, Khoury AC, Wong W, Whitelaw N, Whitelaw G, Joseph RE, et al, P&T (Pharmacy and Therapeutics), 1/1/2006
• Join now to see all

Books/Book Chapters

• Progress with Domperidone, A Gastro kinetic and Antiemetic Agent: Royal Society of Medicine International Congress and Symposium Series No. 36 
  Chapter: Domperidone in Patients with Postprandial Upper Gastrointestinal Distress 
  Gordon SJ and Joseph REAcademic Press Inc. (London) Ltd., and the Royal Society of Medicine, London1981

Abstracts/Posters

• Serum magnesium levels are not affected by renal function in patients receiving split-dose, low-volume sodium picosulfate and magnesium citrate bowel preparation.
  Bertiger G, Jones E, Dahdal D, Joseph RE, 2014 Digestive Diseases Week Annual Meeting, Chicago, IL, 1/4/2014
• Serum magnesium levels are not affected by renal function in patients receiving split-dose low-volume sodium picosulfate and magnesium citrate bowel preparation.
  Bertiger G, Jones E, Dahdal D, Joseph RE, Gastrointest Endosc, 1/1/2014
• Serum magnesium levels are not affected by renal function in patients receiving split-dose low-volume sodium picosulfate and magnesium citrate bowel preparation
  Bertiger G, Jones E, Dahdal D, Joseph RE, Gastrointest Endosc, 1/1/2014
• Colon cleansing in patients with a predictor of a poor preparation: an analysis of the SEE CLEAR I study.
  Bertiger G, Clift S, Krause R, Rex DK, Katz PO, Joseph R, 2013 Digestive Diseases Week Annual Meeting, Orlando, FL, 1/21/2013
• Colon cleansing in the SEE CLEAR I study: an analysis by sex, race, and poverty level.
  Katz PO, Rex DK, Clift S, Joseph R, 2013 Digestive Diseases Week Annual Meeting, Orlando, FL, 1/21/2013
• Patient-Reported Tolerability in the SEE CLEAR Studies: An Analysis of Current and Previous Bowel Preparations in Patients with a Prior Colonoscopy.
  Epstein M, Krause R, Katz PO, Rex DK, and Joseph RE, 2013 Society of Gastroenterology Nurses and Associates, Inc. Annual Course, Austin, TX, 1/17/2013
• Efficacy and safety of a split-dose dual-action, low-volume bowel preparation for colonoscopy: the SEE CLEAR I study.
  Rex D, Katz P, Bertiger G, Masure J, Joseph R, 8th Congress of the European Crohn's and Colitis Organization, Vienna, Austria, 1/15/2013
• Efficacy and safety of a split-dose dual-action, low-volume bowel preparation for colonoscopy: The SEE CLEAR I study.
  Rex D, Katz P, Bertiger G, Masure J, Joseph R, European Crohn's and Colitis Organization Congress, 1/14/2013
• Efficacy and safety of day-before dosing of a dual-action, low-volume bowel preparation for colonoscopy: The SEE CLEAR II study.
  Katz P, Rex D, Epstein M, Masure J, Joseph R, European Crohn's and Colitis Organization Congress, 1/14/2013
• Use of split-dose sodium picosulfate/magnesium citrate (P/MC) bowel preparation for colonoscopy in patients with comorbid diabetes, controlled hypertension, and/or obe...
  Bertiger G, Clift S, Krause R, Joseph R, American College of Gastroenterology 2013, San Diego, CA, 1/13/2013
• Efficacy and safety of a split-dose dual-action, low-volume bowel preparation for colonoscopy: the SEE CLEAR I study.
  Rex D, Katz P, Bertiger G, Masure J, Joseph R, J Crohn's Colitis, 1/1/2013
• Colon cleansing in the SEE CLEAR I study: an analysis by sex, race, and poverty level.
  Katz PO, Rex DK, Clift S, Joseph RE, Gastrointest Endosc, 1/1/2013
• Colon cleansing in patients with predictors of a poor preparation: an analysis of the SEE CLEAR I study.
  Bertiger G, Clift S, Krause R, Rex DK, Katz PO, Joseph RE, Gastrointest Endosc, 1/1/2013
• Use of split-dose sodium picosulfate/magnesium citrate (P/MC) bowel preparation for colonoscopy in patients with comorbid diabetes, controlled hypertension, and/or obe...
  Bertiger G, Clift S, Krause R, Joseph R, Am J Gastroenterol, 1/1/2013
• Split-Dose Administration of a Novel, Dual-Action, Low-Volume Bowel Cleanser for Colonoscopy: Efficacy and Safety Results from the SEE CLEAR I Study.
  Rex DK, Katz PO, Bertiger G, Alderfer V, Joseph RE, ACG (American College of Gastroenterology) Annual Meeting, Las Vegas, NV, 1/23/2012
• Day-Before Administration of a Novel, Dual-Action, Low-volume Bowel Cleanser for Colonoscopy: Efficacy and Safety Results from the SEE CLEAR II Study.
  Katz PO, Rex DK, Epstein M, Grandhi N, Alderfer V, Joseph RE, ACG (American College of Gastroenterology) Annual Meeting, Las Vegas, NV, 1/23/2012
• Split-dose administration of a novel, dual-action low-volume bowel cleanser for colonoscopy: efficacy and safety results from the SEE CLEAR I Study.
  Rex DK, Katz P, Bertiger G, Alderfer V, Joseph R, American College of Gastroenterology 2012 Annual Meeting, Las Vegas, NV, 1/23/2012
• Tolerability and Patient Questionnaire Results from Split-Dose Administration of Picoprep for Colonoscopy: The SEE CLEAR I Study.
  Rex D, Katz P, Bertiger G, Joseph R, Digestive Disease Week Congress, 1/19/2012
• Day-Before Administration of Picoprep for Colonoscopy: Tolerability and Patient Questionnaire Results from the SEE CLEAR II Study.
  Katz P, Rex D, Epstein M, Grandhi N, Joseph R, Digestive Disease Week Congress, 1/19/2012
• Split-Dose Administration of a Novel, Dual-Action, Low-Volume Bowel Cleanser for Colonoscopy: Efficacy and Safety Results from the SEE CLEAR I Study.
  Rex D, Katz P, Bertiger G, Alderfer V, Joseph R, American College of Gastroenterology Congress, 1/19/2012
• Day-Before Administration of a Novel, Dual-Action, Low-Volume Bowel Cleanser for Colonoscopy: Efficacy and Safety Results from the SEE CLEAR II Study.
  Katz P, Rex D, Epstein M, Grandhi N, Alderfer V, Joseph R, American College of Gastroenterology Congress, 1/19/2012
• Patient-Reported Tolerability in the SEE CLEAR I Study: An Analysis of Current and Previous Preparations in Patients with a Prior Colonoscopy.
  Epstein M, Krause R, Katz P, Rex D, Joseph R, Society of Gastroenterology Nurses & Associates Congress, 1/17/2012
• Tolerability and patient questionnaire results from split-dose administration of Picoprep for colonoscopy: the SEE CLEAR I study.
  Rex DK, Katz PO, Bertiger G, Joseph RE, Gastroenterology, 1/1/2012
• Split-dose administration of a novel, dual-action low-volume bowel cleanser for colonoscopy: efficacy and safety results from the SEE CLEAR I Study.
  Rex DK, Katz P, Bertiger G, Alderfer V, Joseph R, Am J Gastroenterol, 1/1/2012
• Relationship between time taken to induce remission of acute mild-to-moderate ulcerative colitis with MMX�mesalazine and subsequent long-term remission rate: Results f...
  Kamm MA, Hanauer SB, Diebold R, Barrett K, Joseph RE, Gut, 15th United European Gastroenterology Week, Paris, 1/29/2007
• Join now to see all

Lectures

• Patients with quiescent mild-to-moderate ulcerative colitis receiving a multiple-daily dose mesalazine formulation can change to once-or twice-daily MMX�mesalazine and... 
  Montreal, Canada - 1/1/2008
• Advances In Ulcerative Colitis 
  Phoenix, AZ; Miami, FL - 1/25/2006
• TARGET study (lumiracoxib) review and perspective with CLASS and VIGOR. 
  Blue Bell, PA - 1/27/2004
• "Effectiveness Evidence to Support Long-term Use" 
  FDA Parklawn Conference Rooms D and E, Rockville, MD - 1/28/2001
• Ischemic colitis - (Drug Induced) 
  Rockville, MD - 1/1/2001
• Gastroenterology-Brain-Gut Axis - Effect of Stress -Gastrointestinal Motility. 
  New Brunswick, NJ - 1/1/1997
• Transporter and Enzymatic Changes in Neonates and Pediatrics: Challenges developing Drugs for Pediatric population. 
  San Antonio, TX
• "Inflammatory Bowel Disease" 
  Multiple locations
• Join now to see all

Other

• Once-Or Twice-Daily MMX Mesalazine (2.4g/Day) Is Effective for The Maintenance Of Remission of Mild-To-Moderate Ulcerative Colitis Regardless of The Mesalazine Dose Or... 
  Colombel JF, Diebold R, Karlstadt R, Barrett K, Joseph R, Shire Pharmaceuticals Inc., Vol. 2, No. 1, pp. 17-17
  Basingstoke, United Kingdom - 1/1/2008
• MMX Mesalazine is an effective treatment for active, mild-to-moderate UC regardless of prior 5-ASA use: a pooled analysis of two placebo-controlled, Phase III Trials, ... 
  Kamm M, Lichtenstein G, Sandborn W, Barrett K, Joseph R, Shire Pharmaceuticals Inc., Vol. 1, No. 1, Pages 18-18
  Wayne, PA - 1/1/2007
• Biologic License Application (BLA) Medical Officer's Review (Remicade®) 
  Joseph RE, Food and Drug Administration
  Rockville, MD - 1/26/2003
• New Drug Application 21-252 Medical Officer's Review (Canasa®). 
  Joseph RE, Food and Drug Administration
  Rockville, MD - 1/5/2002
• Professional development- priority initiatives for CDER Medical Officers CDER News Along the Pike. 
  Raymond E. Joseph, M.D., FACP, FACG, Scheldon Kress, M.D., Markham Luke, M.D., Ph.D., and James Witter, M.D., Ph.D., Center for Drug Evaluation and Research, Volume 8, Issue 1
  1/4/2002
• �Written Request' IND 20987/20-988 Protonix. 
  Joseph RE
  1/19/2001
• �Written Request' IND 53, 733 Nexium. 
  Joseph RE
  1/15/2001
• New Drug Application 21-252 Medical Officer's Review CANASA (mesalamine) suppositories. 
  Joseph RE, Food and Drug Administration
  Rockville, MD - 1/9/2001
• Supplemental New Drug Applications 20-007/S-031, 20-781/S-002, 20-103/S-018, 20�403/S-O10, 20-605/S-005 Medical Reviews (Zofran) 
  Joseph RE, Food and Drug Administration
  Rockville, MD - 1/29/2000
• New Drug Application 21-200 Medical Officer's Review (Zelnorm™)™ 
  Joseph RE, Food and Drug Administration
  Rockville, MD - 1/8/2000
• New Drug Application 21-121 Medical Consult Review (Concerta) 
  Joseph RE, Food and Drug Administration
  Rockville, MD - 1/1/2000
• Current Therapy for Ulcer Disease 
  Joseph RE, Audio-Digest Internal Medicine, Vol. 32, Number 9
  1/8/1985
• Gastric Ulcer. 
  Joseph RE, Audio-Digest International Medicine
  1/16/1983
• Final Autopsy Reports and Three Johns Hopkin's CPC's 
  RE Joseph, M.D., Johns Hopkins Press (1973-1975)
  1/1/1975
• Join now to see all